• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Codexis Inc. (Amendment)

    2/13/24 5:02:32 PM ET
    $CDXS
    Major Chemicals
    Industrials
    Get the next $CDXS alert in real time by email
    SC 13G/A 1 tv0633-codexisinc.htm SCHEDULE 13G/A codexisinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 2)*

    Name of issuer:  Codexis Inc

    Title of Class of Securities:  Common Stock

    CUSIP Number:  192005106

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  192005106

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    41,416

    7.  SOLE DISPOSITIVE POWER

    4,063,801

    8.  SHARED DISPOSITIVE POWER

    64,627

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,128,428

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    5.91%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Codexis Inc

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    200 Penobscot Drive
    Redwood City, CA 94063-4718

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    192005106

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $CDXS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CDXS

    DatePrice TargetRatingAnalyst
    8/19/2024Buy → Hold
    The Benchmark Company
    6/3/2024$5.00Buy
    Jefferies
    5/30/2024$11.00Overweight
    Cantor Fitzgerald
    2/29/2024Hold → Buy
    The Benchmark Company
    11/7/2023Buy → Hold
    The Benchmark Company
    8/7/2023$21.00 → $4.00Outperform → Market Perform
    TD Cowen
    5/9/2023Buy → Neutral
    H.C. Wainwright
    3/31/2022$35.00Overweight
    Piper Sandler
    More analyst ratings

    $CDXS
    SEC Filings

    View All

    SEC Form S-8 filed by Codexis Inc.

    S-8 - CODEXIS, INC. (0001200375) (Filer)

    8/13/25 5:15:35 PM ET
    $CDXS
    Major Chemicals
    Industrials

    SEC Form 10-Q filed by Codexis Inc.

    10-Q - CODEXIS, INC. (0001200375) (Filer)

    8/13/25 4:14:45 PM ET
    $CDXS
    Major Chemicals
    Industrials

    Codexis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - CODEXIS, INC. (0001200375) (Filer)

    8/13/25 4:08:46 PM ET
    $CDXS
    Major Chemicals
    Industrials

    $CDXS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Codexis Reports Second Quarter 2025 Financial Results

    Announces revenue of $15.3M vs $14.1M analyst consensus estimate Six presentations featured ECO Synthesis® platform at 2025 TIDES USA annual meeting, including three from leading CDMO collaborators $27.3M raised via ATM facility and Innovatus loan to support expansion of ECO Synthesis REDWOOD CITY, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced financial results for the second quarter ended June 30, 2025, and provided a business update. "The second quarter marked a key strategic shift for Codexis," said Stephen Dilly, MBBS, PhD, Chairma

    8/13/25 4:05:00 PM ET
    $CDXS
    Major Chemicals
    Industrials

    Codexis to Report Second Quarter 2025 Financial Results on August 13

    REDWOOD CITY, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced that it will report its financial results for the second quarter of 2025 on Wednesday, August 13, 2025, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update. Participants may access the live webcast on the Codexis Investor Relations website, where it will be archived for 90 days. The live call can be accessed by dialing 877-705-2976 (domestic) or 2

    7/30/25 4:05:00 PM ET
    $CDXS
    Major Chemicals
    Industrials

    Codexis' Landmark Presentations at TIDES USA Highlight Reproducibility and Process Simplification of the ECO Synthesis Platform for Manufacturing siRNA

     Presentations by leading siRNA CDMOs, Bachem, Nitto Avecia, and ST Pharm, highlight performance and transferability of Codexis double-stranded RNA ligases Management to host conference call today at 8 am Eastern Time to discuss data REDWOOD CITY, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, presented data at the TIDES USA annual meeting in San Diego, California. Codexis' presentations showcased its proprietary ECO Synthesis platform's ability to support siRNA manufacturing by reducing purification costs, improving process performance, and demon

    5/22/25 7:00:00 AM ET
    $CDXS
    Major Chemicals
    Industrials

    $CDXS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Opaleye Management Inc. bought $227,921 worth of shares (85,000 units at $2.68) (SEC Form 4)

    4 - CODEXIS, INC. (0001200375) (Issuer)

    8/4/25 4:38:06 PM ET
    $CDXS
    Major Chemicals
    Industrials

    Large owner Opaleye Management Inc. bought $28,161 worth of shares (10,000 units at $2.82) (SEC Form 4)

    4 - CODEXIS, INC. (0001200375) (Issuer)

    7/31/25 4:05:07 PM ET
    $CDXS
    Major Chemicals
    Industrials

    Large owner Opaleye Management Inc. bought $282,000 worth of shares (100,000 units at $2.82) (SEC Form 4)

    4 - CODEXIS, INC. (0001200375) (Issuer)

    7/22/25 4:05:11 PM ET
    $CDXS
    Major Chemicals
    Industrials

    $CDXS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Codexis downgraded by The Benchmark Company

    The Benchmark Company downgraded Codexis from Buy to Hold

    8/19/24 8:50:44 AM ET
    $CDXS
    Major Chemicals
    Industrials

    Jefferies resumed coverage on Codexis with a new price target

    Jefferies resumed coverage of Codexis with a rating of Buy and set a new price target of $5.00

    6/3/24 8:45:11 AM ET
    $CDXS
    Major Chemicals
    Industrials

    Cantor Fitzgerald initiated coverage on Codexis with a new price target

    Cantor Fitzgerald initiated coverage of Codexis with a rating of Overweight and set a new price target of $11.00

    5/30/24 7:33:26 AM ET
    $CDXS
    Major Chemicals
    Industrials

    $CDXS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Opaleye Management Inc. bought $227,921 worth of shares (85,000 units at $2.68) (SEC Form 4)

    4 - CODEXIS, INC. (0001200375) (Issuer)

    8/4/25 4:38:06 PM ET
    $CDXS
    Major Chemicals
    Industrials

    Large owner Opaleye Management Inc. bought $28,161 worth of shares (10,000 units at $2.82) (SEC Form 4)

    4 - CODEXIS, INC. (0001200375) (Issuer)

    7/31/25 4:05:07 PM ET
    $CDXS
    Major Chemicals
    Industrials

    Large owner Opaleye Management Inc. bought $282,000 worth of shares (100,000 units at $2.82) (SEC Form 4)

    4 - CODEXIS, INC. (0001200375) (Issuer)

    7/22/25 4:05:11 PM ET
    $CDXS
    Major Chemicals
    Industrials

    $CDXS
    Leadership Updates

    Live Leadership Updates

    View All

    Codexis Appoints Cynthia Collins to Board of Directors

    REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of Cynthia Collins to the Company's Board of Directors. "I am thrilled to welcome Cindy to our Board," said Stephen Dilly, MBBS, PhD, Chairman and Chief Executive Officer at Codexis. "She has been at the forefront of innovation across multiple therapeutic modalities and brings a wealth of knowledge about the CDMO landscape. I look forward to her valuable guidance as we continue expanding the commercial footprint of our ECO Synthesis toolbox." Ms. Collins added,

    4/1/25 7:00:00 AM ET
    $CDXS
    Major Chemicals
    Industrials

    Codexis Appoints Arthur Levin, PhD, to Strategic Advisory Board

    REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of Arthur Levin, PhD, to the Company's Strategic Advisory Board (SAB). Dr. Levin is a founding member of Avidity Biosciences, a biopharmaceutical company committed to delivering a new class of RNA therapeutics called antibody oligonucleotide conjugates, and currently serves on its Board of Directors. He brings three decades of experience developing oligonucleotides to Codexis as it continues to onboard customers for its Enzyme Catalyzed Oligonucleotide (ECO) Synthesis™ manufact

    2/6/25 4:05:30 PM ET
    $CDXS
    Major Chemicals
    Industrials

    Codexis Appoints Christos Richards to Board of Directors

    REDWOOD CITY, Calif., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of Christos Richards to the Company's Board of Directors. "I am delighted to welcome Christos to our Board. His broad and deep knowledge and understanding of the life sciences industry will be invaluable as we continue the transformation of Codexis," said Stephen Dilly, MBBS, PhD, Chairman and Chief Executive Officer at Codexis. Mr. Richards added, "As a longstanding partner to the biopharmaceutical industry, I'm well aware of the potential of Codexis' proprietary technologies

    1/16/25 4:05:27 PM ET
    $CDXS
    Major Chemicals
    Industrials

    $CDXS
    Financials

    Live finance-specific insights

    View All

    Codexis Reports Second Quarter 2025 Financial Results

    Announces revenue of $15.3M vs $14.1M analyst consensus estimate Six presentations featured ECO Synthesis® platform at 2025 TIDES USA annual meeting, including three from leading CDMO collaborators $27.3M raised via ATM facility and Innovatus loan to support expansion of ECO Synthesis REDWOOD CITY, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced financial results for the second quarter ended June 30, 2025, and provided a business update. "The second quarter marked a key strategic shift for Codexis," said Stephen Dilly, MBBS, PhD, Chairma

    8/13/25 4:05:00 PM ET
    $CDXS
    Major Chemicals
    Industrials

    Codexis to Report Second Quarter 2025 Financial Results on August 13

    REDWOOD CITY, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced that it will report its financial results for the second quarter of 2025 on Wednesday, August 13, 2025, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update. Participants may access the live webcast on the Codexis Investor Relations website, where it will be archived for 90 days. The live call can be accessed by dialing 877-705-2976 (domestic) or 2

    7/30/25 4:05:00 PM ET
    $CDXS
    Major Chemicals
    Industrials

    Codexis' Landmark Presentations at TIDES USA Highlight Reproducibility and Process Simplification of the ECO Synthesis Platform for Manufacturing siRNA

     Presentations by leading siRNA CDMOs, Bachem, Nitto Avecia, and ST Pharm, highlight performance and transferability of Codexis double-stranded RNA ligases Management to host conference call today at 8 am Eastern Time to discuss data REDWOOD CITY, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, presented data at the TIDES USA annual meeting in San Diego, California. Codexis' presentations showcased its proprietary ECO Synthesis platform's ability to support siRNA manufacturing by reducing purification costs, improving process performance, and demon

    5/22/25 7:00:00 AM ET
    $CDXS
    Major Chemicals
    Industrials

    $CDXS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Codexis Inc.

    SC 13G - CODEXIS, INC. (0001200375) (Subject)

    9/26/24 9:27:32 AM ET
    $CDXS
    Major Chemicals
    Industrials

    Amendment: SEC Form SC 13G/A filed by Codexis Inc.

    SC 13G/A - CODEXIS, INC. (0001200375) (Subject)

    9/18/24 4:50:02 PM ET
    $CDXS
    Major Chemicals
    Industrials

    SEC Form SC 13G filed by Codexis Inc.

    SC 13G - CODEXIS, INC. (0001200375) (Subject)

    7/12/24 4:15:13 PM ET
    $CDXS
    Major Chemicals
    Industrials